Oral Administration of Meloxicam and Flunixin Meglumine Have Similar Analgesic Effects After Lipopolysaccharide-Induced Inflammatory Response in Thoroughbred Horses.
Authors: Urayama Shuntaro, Tanaka Akane, Kusano Kanichi, Sato Hiroaki, Muranaka Masanori, Mita Hiroshi, Nagashima Tsuyoshi, Matsuda Hiroshi
Journal: Journal of equine veterinary science
Summary
# Editorial Summary This 2023 study directly compared meloxicam and flunixin meglumine—two NSAIDs commonly used for endotoxaemia in horses—by administering lipopolysaccharide (LPS) to 15 Thoroughbreds and treating them with either meloxicam (0.6 mg/kg orally), flunixin meglumine (1.1 mg/kg orally), or placebo 30 minutes post-challenge. Both active treatments significantly reduced pain scores and body temperature compared to placebo, with no meaningful difference between the two drugs; interestingly, whilst flunixin meglumine produced lower TNF-α and cortisol levels, other systemic inflammatory markers including heart rate, respiratory rate, hoof wall temperature, and white cell counts responded similarly between the two groups. The findings suggest that meloxicam's COX-2 selective mechanism achieves comparable analgesic and anti-inflammatory efficacy to the nonselective flunixin meglumine in this endotoxaemic model, potentially offering a safer alternative given flunixin meglumine's well-documented gastrointestinal side effects. For practitioners managing sepsis-related conditions in horses, these results support meloxicam as a viable first-line option where SIRS/endotoxaemia is suspected, particularly in cases where prolonged NSAID therapy is anticipated or where gastrointestinal integrity is already compromised.
Read the full abstract on PubMed
Practical Takeaways
- •Meloxicam offers comparable pain relief to flunixin meglumine in SIRS/endotoxemia cases, with potential advantage of fewer GI adverse effects in clinical practice.
- •Consider meloxicam as an alternative to flunixin meglumine for horses with endotoxemia, particularly those at risk for NSAID-induced gastrointestinal complications.
- •While flunixin meglumine showed stronger suppression of specific inflammatory markers (TNF-α, cortisol), the clinical significance of this difference did not translate to superior pain control in this study.
Key Findings
- •Meloxicam and flunixin meglumine produced similar analgesic effects and pain score reduction in LPS-challenged horses, with both significantly lower than placebo.
- •Both meloxicam and flunixin meglumine reduced body temperature similarly compared to placebo group.
- •Flunixin meglumine produced lower TNF-α and cortisol levels than meloxicam, suggesting stronger systemic anti-inflammatory effect.
- •Heart rates, respiratory rates, hoof wall surface temperature, and leukocyte counts changed similarly between meloxicam and flunixin meglumine groups.